Investor profile
Astellas Venture Management
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
AVM is the wholly-owned venture capital organization within Astellas Pharma, dedicated to supporting pre-clinical, cutting-edge science that can bring value to patients. For over 20 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or catalyze new directions in discovery research. The strength of AVM lies in its 'Pharma View' — deep pharmaceutical industry expertise that it leverages to support portfolio companies and serve as a liaison between them and Astellas Pharma, facilitating dialogue for future collaborations, licensing, and R&D partnerships. AVM targets innovative therapeutic approaches aligned with Astellas's R&D strategy, prioritizing companies with programs and technologies to fulfill unmet medical needs, with a focus on preclinical-stage privately owned biotech companies.
Notable quotes
“AVM's role is to gain access to assets and technologies that we anticipate may have direct impact on Astellas' pipeline in the foreseeable future. Since AVM is a purely strategic investor, with no overt interest in financial ROI, I like to look carefully at the development plan being proposed, the incorporation of decision tree-like thinking and some cuts and bruises on the management team as evidence of having navigated adversity with success. I like to sense that the team will follow the science and bring it to its greatest potential with respect to impact on Astellas' pipeline, as opposed to planning for the quickest, richest exit.”
“This environment of pure scientific innovation instilled in me a great appreciation for scientist-entrepreneurs and the invaluable vision and commitment they bring to their ventures. That tendency persists as my team encounters new investment opportunities — I enjoy hearing business strategies inspired by scientific Founders' vision and ambition.”
“If at all possible, it is highly valuable to have someone on the team with thorough, recent hands-on experience in these spaces as a drug development scientist. The space moves very quickly with technical innovation and it is extremely difficult to understand the risks and upsides without practical familiarity with the actual work being proposed.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Solu Therapeutics | Series A | $41m | 2025-04-09 |
| Syntax Bio | Series A | — | 2024-01-01 |
| NeoPhore | Series A | $13m | 2024-02-01 |
| Orna Therapeutics | Series A | — | 2021-02-24 |
| Casma Therapeutics | Series A | — | 2020-01-01 |
| Catamaran Bio | Series A | — | 2021-01-01 |
| Mogrify | Series A | — | 2020-01-01 |
| Bicycle Therapeutics | Series A | — | 2018-01-01 |
| PhoreMost | Series A | — | 2021-01-01 |
| Shinobi Therapeutics | Seed | — | 2022-01-01 |
Frequent co-investors
Fit check
Is Astellas Venture Management a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit